Le Lézard
Classified in: Health
Subjects: TRI, FDA

LaunchPad Medical Received FDA Approval to Initiate a Clinical Study

LOWELL, Mass., Sept. 12, 2019 /PRNewswire/ -- LaunchPad Medical, Inc. has received approval from the U.S. Food and Drug Administration to initiate a two-site, 20-patient pilot clinical study to examine the safety and efficacy of the company's bone adhesive biomaterial (known as Tetranite®) to immediately stabilize dental implants for tooth extractions.

Patients will be enrolled in the study if an extraction site is too large for dental implants to achieve primary stability through conventional mechanical engagement, which is often the case.  Instead, the use of Tetranite will allow for the immediate placement of implants and, in many cases, obviate a costly, complex, and lengthy bone grafting process, greatly accelerating the overall treatment timeframe for many patients.

"We are excited to take the next step in commercializing this promising bone adhesive technology that has the opportunity to improve and significantly accelerate the current treatment paradigm for dental implant procedures," said LaunchPad Medical's Chief Executive Officer, Brian Hess.  "Having also just received investigational review board (IRB) approval, we are ready to start enrolling patients at our clinical sites. This marks a significant milestone since it is the first-in-man trial based on this technology platform."

The unique properties of Tetranite include the ability to provide immediate fixation of fractured bone fragments and stabilization of metal implants to bone.  In multiple animal studies this adhesive has been shown to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices.  Existing data has also shown that Tetranite is resorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth.  LaunchPad Medical's Tetranite technology has not yet been approved for commercial use.

About LaunchPad Medical, Inc.

LaunchPad Medical, Inc. is a medical device company engaged in the development and commercialization of a novel injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®.  The Company's initial focus with this technology is for use in the dental market; however, the company is also working to develop adhesive applications in the broader orthopedics market.  LaunchPad operates out of the Massachusetts Medical Device Development Center (M2D2), an accelerator program for medical devices.

SOURCE LaunchPad Medical, Inc.

These press releases may also interest you

at 07:50
SullivanCotter, the nation's leading independent consulting firm in the assessment and development of total rewards programs and workforce solutions for the health care industry and not-for-profit sector, welcomes new Principal, Amber Duncan. She...

at 07:45
Glooko, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA...

at 07:45
Dialogue, the leading Canadian telemedicine platform, today announces a groundbreaking partnership with Doctor On Demand, the leading virtual care provider in the United States. Through this partnership, enterprise clients will now have the option to...

at 07:35
Sage Therapeutics , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it plans to advance SAGE-718, a novel,...

at 07:35
Biotia, a health tech company leveraging next-generation DNA sequencing (NGS) and artificial intelligence (AI) software for precision infectious disease detection and diagnosis, today announced an oversubscribed $2.4M seed raise and expanded...

at 07:35
Bristol-Myers Squibb Company today announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC-486 as maintenance therapy in a broad population of patients with front-line, newly diagnosed acute myeloid leukemia...

News published on 12 september 2019 at 13:44 and distributed by: